Biological methylation and hydride formation of metals and metalloids are ubiquitous environmental processes that can lead to the formation of chemical species with significantly increased mobility and toxicity. Whereas much is known about the interaction of metal(loid)s with microorganisms in environmental settings, little information has been gathered on respective processes inside the human body as yet. Here, we studied the biotransformation and excretion of bismuth after ingestion of colloidal bismuth subcitrate (215 mg of bismuth) to 20 male human volunteers. Bismuth absorption in the stomach and upper intestine was very low, as evidenced by the small quantity of bismuth eliminated via the renal route. Total bismuth concentrations in blood increased rapidly in the first hour after ingestion. Most of the ingested bismuth was excreted via feces during the study period. Trace levels of the metabolite trimethylbismuth [(CH 3 ) 3 Bi] were detected via low temperaturegas chromatography/inductively coupled plasma-mass spectrometry in blood samples and in exhaled air samples. Concentrations were in the range of up to 2.50 pg/ml (blood) and 0.8 to 458 ng/m 3 (exhaled air), with high interindividual variation being observed. Elimination routes of bismuth were exhaled air (up to 0.03‰), urine (0.03-1.2%), and feces. The site of (CH 3 ) 3 Bi production could not be identified in the present study, but the intestinal microflora seems to be involved in this biotransformation if accompanying ex vivo studies are taken into consideration.
It is a well known fact that the toxicity of metal(loid)s is essentially dependent on the chemical form, i.e., on the species of the element in question (Craig, 2003; Dopp et al., 2004; Hirner and Emons, 2004) . In particular, alkylation often seems to considerably increase the toxic potential of metal(loid)s. Many studies have shown that in the environment methylated and also, in some cases, hydride species can be formed by different mechanisms and from a variety of metal(loid)s (Craig, 2003) . In particular, microorganisms, e.g., bacteria and fungi, have been reported to be involved in this specific kind of conversion (Thayer, 2002) .
In contrast to the considerable knowledge that has accumulated on the interaction of microorganisms with metal(loid)s in the environment, a paucity of information is currently available on the respective processes inside the human body. This lack of knowledge is particularly striking in view of the fact that certain segments of the digestive tract, namely, the oral cavity and the colon, are colonized by myriads of bacteria. The difficulty of analyzing metal(loid) organic compounds at trace and even ultratrace levels might at least partly account for this information gap.
After a pilot study with three volunteers , we performed an ingestion experiment with bismuth, administering this element as a single p.o. dose to 20 male volunteers in the form of a therapeutically used colloidal bismuth subcitrate compound. Bismuth was chosen as the element of interest for a number of reasons:
1. Humans are exposed to bismuth via pharmaceutical products (Menge et al., 1992) and ubiquitous bismuth-containing cosmetics. For example, colloidal bismuth subcitrate and other bismuth compounds are used in the treatment of ulcers and, more specifically, in the eradication of Helicobacter pylori. Bismuth subsalicylate is present in relatively high concentrations (1-2%) in over-the-counter indigestion remedies. 2. Inorganic bismuth compounds have been shown to elicit low toxicity [e.g., the LD 50 of bismuth oxychloride is 22,000 mg/kg (rat, p.o.)]. Neurological disorders observed after the p.o. intake of bismuth salts typically followed the ingestion of up to 20 g/day over a period of 20 days/month (Slikkerveer and de Wolff, 1989; Sun et al., 2004) . Nevertheless, toxic effects are rarely observed if bismuthcontaining pharmaceuticals are taken in the recommended doses, which is probably because of the extremely low absorption of this metal (Sun et al., 2004) . 3. Bismuth metabolism in humans is as yet unknown. Some data on transport processes and bismuth protein interactions have been reported (Sun et al., 2004) . 4. Bismuth is known to be methylated by microorganisms in the environment as described above. The formation of trimethylbismuth [(CH 3 ) 3 Bi] and bismuth trihydride by Methanobacterium formicicum has been experimentally shown in sewage sludge (Michalke et al., 2000 (Michalke et al., , 2002 . Some of these microorganisms are known components of the human intestinal microflora. 5. Analysis of bismuth and its metabolites is facilitated by the fact that background concentrations of bismuth species in the human population are very low [G. Wiesmueller (Environmental Specimen Bank, Muenster, Germany), personal communication].
Materials and Methods
Study Population, Study Design, and Sampling. The study included 20 healthy, male volunteers (age ϭ 27.2 Ϯ 2.4 years; weight ϭ 82.5 Ϯ 11.6 kg; body mass index ϭ 25 Ϯ 4 kg/m 2 ) living in Essen, Germany, who were enrolled in this investigation. One of them participated twice, so that 21 data sets were obtained. No study participant took any form of medication, and all were judged to be healthy based on their medical history, a physical examination, and a routine laboratory screening. The participants were nonsmokers and had no history of metabolic disorder or disease of the gastrointestinal tract. Investigations were carried out at the Department of Hygiene and Occupational Medicine at the University Hospital of Essen, Germany. All the participants gave informed written consent. The study was approved by the Ethics Committee of the University Hospital of Essen and was in accordance with the principles laid down in the Declaration of Helsinki.
At 9:00 AM the first day, two tablets of colloidal bismuth subcitrate (De-Noltab; Yamanouchi Europe B.V., Leiderdorp, The Netherlands) containing a total of 215 mg of bismuth were taken by each individual together with some tap water. The volunteers were asked not to chew the tablets.
Samples of exhaled air and blood were taken immediately before bismuth ingestion (t ϭ 0) and 1, 2, 4, 8, 24, and 48 h thereafter; blood was additionally collected 0.5, 32, and 56 h after ingestion. Urine and feces samples were collected before the onset of the study and subsequently according to urinary/ fecal urge during the study period. All the participants were asked to note urine volume, fecal mass, as well as the time of sampling. Exhaled air was collected in 10-liter Tedlar bags (Supelco, Taufkirchen, Germany) and then transferred to traps [custom-made, borosilicate glass, length 20 cm, i.d. 8 mm, filled with 1.59 g of 10% SP-2100 on 80/100 Supelcoport (Supelco, Bellefonte, PA) and used after conditioning for 16 h at 280°C] at Ϫ78°C (ethanol/liquid nitrogen) and analyzed immediately as described below. Whole blood (citrate stabilized, 10 ml of S-Monovette; SARSTEDT, Nuernbrecht-Rommelsdorf, Germany), urine, and feces samples were stored at Ϫ80°C until analysis.
Total Metal Analysis. Bismuth concentrations in blood, urine, and feces were determined by inductively coupled plasma mass spectrometry (ICP-MS) after microwave digestion of the samples (MARS 5; CEM, Kamp-Lintfort, Germany). Digestion was performed in closed perfluoroalkoxy vessels (XP 1500 Plus; CEM), which contained nitric acid (65%, sub-boiled) and 2 ml of hydrogen peroxide (30%, Suprapur; Merck, Darmstadt, Germany). Sample volumes/weights and respective aliquot additions of nitric acid were as follows: blood, 2 ml/3 ml; urine, 4 ml/3 ml; and feces, 0.1 to 0.5 g/4 ml. The microwave parameters are presented as supplemental data (Supplemental Table 1 ). The digestate was diluted with ultrapure water (18.2 M⍀ ⅐ cm, Purelab Ultra; ELGA LabWater, Celle, Germany) to a final volume of 30 ml (blood and urine) or 40 ml (feces) before analysis. Feces samples with a high bismuth content were diluted to 1 in 100.
ICP-MS (Agilent 7500a; Agilent Technologies, Waldbronn, Germany) conditions, such as radio frequency power, ion lens voltages, gas flows, and so on, were adjusted to obtain robust plasma conditions and to minimize matrix effects. Holmium (5 ng/ml) as internal standard was added, and the solutions were delivered at 0.3 ml/min to a microflow nebulizer and routed through a double-pass Scott-type spray chamber (both from AHF Analysentechnik, Tuebingen, Germany) cooled to 2°C. Quantification was performed by external calibration (blank, 0.02, 0.05, 0.2, 0.4, 0.7, 1, 4, 7, 10, 20, 30 , and 40 g/l bismuth) and validated by analyzing certified reference materials (Seronorm Trace Elements in Whole Blood, Levels 1 and 2/Urine; SERO AS, Billingstad, Norway). In the case of feces samples, there was no certified reference material available. The limits of detection and limits of quantification (3 -and 10 -criterion) were determined daily (typically, blood 0.03, 0.1 g/l; urine 0.001, 0.003 g/l; feces 0.44, 1.46 g/kg). All of the samples were measured in duplicate.
Identification of (CH 3 ) 3 Bi. The (CH 3 ) 3 Bi standard (VeZerf Laborsynthesen, Idar-Oberstein, Germany) was identified via parallel electron impact mass spectrometry and ICP-MS detection after gas chromatography separation (GC/ EI-MS/ICP-MS) as described elsewhere (Koesters et al., 2005) . Gas chromatographic (GC) separation was performed on a 6890 N gas chromatographic system (Agilent Technologies), which was equipped with a UNIS 2000 inlet system (Joint Analytical Systems, Moers, Germany) for programmed temperature vaporization after purge and trap sampling and a capillary column (HP-5MS, 0.25 mm ϫ 30 m ϫ 0.25 m).
Two detection systems were used simultaneously: a 5973 N electron impact mass spectrometry (EI-MS) and a 7500a ICP-MS (both from Agilent Technologies). Parallel detection was realized with a postcolumn split inside the GC oven connecting the column with two uncoated capillary lines leading to the particular detectors. Operation parameters are listed in Table 2 of the Supplemental Data.
Bismuth Speciation Analysis. (CH 3 ) 3 Bi present in exhaled air was determined via low temperature (LT)-GC/ICP-MS as described by Wickenheiser et al. (1998) : a 3-liter subsample (three subsamples of 3 liters per Tedlar bag) was sucked slowly with a vacuum pump and a gas clock (Trommel-Gaszaehler TG 1/6; Ritter Apparatebau, Bochum, Germany) through a trap held at Ϫ78°C. At the same time, the chromatographic column temperature was maintained at Ϫ196°C. After removal of the ethanol/liquid nitrogen mixture, the analytes were thermally desorbed from the trap and separated via GC. The GC column was warmed up from Ϫ196°C up to 5.8°C at room temperature within 5 min and subsequently heated at a rate of 35°C/min to a final temperature of 150°C using a resistance wire (Transformator LTS 606; Thalheimer Transformatorenwerke, Thalheim, Germany). Transfer to the ICP-MS was accomplished via a fluorinated, ethylene propylene tube (length 80 cm, i.d. 0.75 mm, o.d. 1/16 inch; CS-Chromatographie, Langerwehe, Germany). To ensure a homogenous temperature distribution, the transfer line was inserted into a copper tubing (i.d. 1/16 inch, o.d. 1/8 inch), which was heated to 150°C using a resistance wire (Power Supply, Typ 3252; Statron, Fuerstenwalde, Germany).
(CH 3 ) 3 Bi in whole blood samples was analyzed in a similar manner to the analytes in exhaled air. A three-necked round-bottom flask (100 ml) containing 1 to 4 ml of the sample, 10 ml of ultrapure water, and 100 l of antifoam/ ultrapure water [1 in 100 (v/v), Antifoam 289; Sigma-Aldrich, Taufkirchen, Germany] was purged with 60 ml/min helium (5.0; Air Liquide, Duesseldorf, Germany) for 2 min to remove oxygen. Then, blood samples were transferred from closed vessels through a septum (butyl-Teflon-rubber; CS-Chromatographie) into the flask via a syringe (5 ml, Becton Dickinson Discardit II; BD Biosciences, Franklin Lakes, NJ) and disposable hypodermic needle (Sterican 0.60 ϫ 30 mm; Braun, Melsungen, Germany) to prevent a loss of the analyte. The blood gases were purged by 60 ml/min helium for 8 min and trapped quantitatively in custom-made U-tubes as described above, and analyzed by LT-GC/ICP-MS (Grüter et al., 2000) . The quantitative transfer of blood gases was verified by repetitive purging (n ϭ 2) of selected samples. All of the blood samples were measured in duplicate.
In both cases chromatography was carried out using a packed column (custom-made, borosilicate glass, length 80 cm, i.d. 8 mm, filled with 6.38 g of 10% SP-2100 on 80/100 Supelcoport and conditioned for 16 h at 280°C). (CH 3 ) 3 Bi was measured by ICP-MS at a mass-to-charge ratio of m/z 209 (corresponding to 209 Bi). Quantification of (CH 3 ) 3 Bi was achieved by integration of the gauss-type signal at a retention time of 307.1 Ϯ 5 s and interaggregate calibration (IAC) (Feldmann, 1997) . IAC uses inorganic aqueous standards for species-independent quantification after separation of volatile species via GC and returns the effective nebulizer mass flow by differential weighting of the aspirated standard solution and the spray chamber drain.
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at ASPET Journals on March 30, 2017 dmd.aspetjournals.org 205 Thallium added via the nebulizer was used as a continuous internal standard to compensate detector drift. This method was used because quantification procedures such as isotope dilution mass spectrometry or standard addition could not be applied for a variety of reasons ( 209 Bi is monoisotopic and therefore isotope dilution mass spectrometry is not possible; standards are unstable and therefore difficult to handle). Limits of detection/limits of quantification of (CH 3 ) 3 Bi were determined according to the 3 -and 10 -criterion (typically, exhaled air 0.1, 0.3 ng/m 3 ; blood 0.01, 0.04 pg/ml). Creatinine Measurement. Creatinine concentrations in urine were determined by an ADVIA Chemistry System 1650 (Bayer Healthcare, Leverkusen, Germany), which is based on the reaction of creatinine with picric acid under alkaline conditions. The formation rate of the colored complex is proportional to the creatinine concentration (Tietz, 1995) .
Data Expression and Data Analysis. Concentrations of the bismuth species in exhaled air, blood, urine, and feces are presented as mean Ϯ S.D. or as ranges. Total bismuth concentrations in blood were fitted by an exponential curve, and the effective half-life was taken from the rapid elimination phase.
The mass of exhaled bismuth was estimated based on the concentrationversus-time curve and the average respiratory volume of 0.5 m 3 /h in rest. The area under the curve (AUC) was calculated by creating a step function with the steps being ordered symmetrically between two sampling times.
Results
Disposition and Elimination of Bismuth. Analysis of total bismuth concentrations in blood following uptake of colloidal bismuth subcitrate revealed similar profiles in all the study participants. No bismuth was detected in preingestion samples of the participants. The bismuth concentration typically increased to a maximum within the first hour after ingestion (Fig. 1 ) and subsequently decreased with half-lives of approximately 1.6 Ϯ 0.7 h. A significant variation in the maximum blood bismuth concentrations was observed between the individuals, with the maximum bismuth concentration ranging from 1.3 to 158.8 g/l (Supplemental Data Table 3) .
A total of 0.03 to 1.2% (0.06 -2.51 mg) of the ingested bismuth was eliminated renally during the study period, and 68 Ϯ 16% of the absorbed bismuth was excreted in the first 12 h after ingestion, mostly with the first urine after ingestion of the bismuth-containing pharmaceutical. A high interindividual variation in excretion maxima (height and time) was observed with maximum urinary bismuth concentrations being in the range from 0.02 to 12.8 mg/l. A record of the renally eliminated bismuth is presented in Supplemental Data Table 3 .
In contrast to the urinary data, the maxima of the fecal bismuth concentrations ranged from 0.06 to 2.36 g/kg (wet weight), amounting to a total excretion of typically more than 99% of the ingested bismuth during the study period. As feces samples were not given at regular intervals by the volunteers, and as the respective quantities may not have been accurately measured and reported, the percentage of bismuth excreted via feces was calculated by subtraction of the exhaled and the renally eliminated bismuth from the totally ingested bismuth; the bismuth deposition in the body was neglected in this calculation. In another study, Boertz (2008) has found that 91 to 93% of the ingested bismuth is eliminated via the feces within 5 days after ingestion of colloidal bismuth subcitrate. This indicates that a few percent are stored in the human body or are eliminated via alternative pathways. In summary, the analysis of total bismuth concentrations in urine and feces samples indicated that fecal excretion was the primary excretion route for bismuth compounds. The standard deviations of the total bismuth concentrations in blood and urine were lower than 3%. In feces samples, relative standard deviations were in the range from 5 to 52%. A lack of homogeneity in some fecal samples is the likely cause of the larger relative standard deviations observed.
The creatinine concentrations in the urine samples were in the range from 0.09 to 3.78 g/l. There was no obvious relationship between the creatinine concentrations and the respective bismuth levels.
Identification and Quantification of (CH 3 ) 3 Bi. A (CH 3 ) 3 Bi standard was analyzed in parallel by ICP-MS and EI-MS after GC separation (GC/EI-MS/ICP-MS) (Koesters et al., 2005) , and its identity was verified by the respective mass spectrum (supplemental data).
The EI mass spectrum of (CH 3 ) 3 Bi (measured at 70 eV) shows four dominant signals at m/z ϭ 254, 239, 224, and 209. Whereas the signal at m/z ϭ 254 represents the molecular ion, the others reflect the successive loss of three methyl groups. Simultaneously 209 Bi was detected at a mass-to-charge ratio of m/z 209 in the ICP-MS component of this hyphenated technique.
The retention time of the standard compound was determined via LT-GC/ICP-MS. Finally, (CH 3 ) 3 Bi in blood and exhaled air samples was identified based on the retention time obtained (307.1 Ϯ 5 s) via LT-GC/ICP-MS (Fig. 2) . (CH 3 ) 3 Bi could be determined in at least one sample of all the participants. The number of participants who have (CH 3 ) 3 Bi in exhaled air or blood at specific time intervals is shown in Table 1 .
A former pilot study indicated that the volatile bismuth species dimethylbismuth hydride [(CH 3 ) 2 BiH], methylbismuth dihydride (CH 3 BiH 2 ), and bismuth trihydride (BiH 3 ) may also be present in exhaled air. However, this observation could not be corroborated in the present study. (CH 3 ) 3 Bi was the only volatile bismuth species detected in blood or breath samples.
Kinetics of (CH 3 ) 3 Bi. In most samples of exhaled air, (CH 3 ) 3 Bi was detectable for the first time typically 4 h after ingestion. The maximum concentrations were reached after 8 h in most of the participants exhibiting a high interindividual variation, which ranged from 0.8 to 458 ng/m 3 (Supplemental Data Table 4 ). Up to 5.4 g of the ingested bismuth (equivalent to 0.03‰) was eliminated via exhalation during the first 48 h.
(CH 3 ) 3 Bi was also detected in blood samples, namely, in concentrations of up to 2.5 pg/ml. The concentration-versus-time profiles of (CH 3 ) 3 Bi in blood were similar to the corresponding profiles of (CH 3 ) 3 Bi in exhaled air. Two typical profiles representing the curve shape in most participants are shown in Fig. 3, a and b . In 7 of 20 volunteers, the (CH 3 ) 3 Bi concentrations in blood were below the limit of detection at all the sampling times (Supplemental Data Table 4 ).
In contrast, no obvious relationship was found between the total bismuth concentrations in blood and the respective (CH 3 ) 3 Bi concen- (Fig. 4, a and b) . Blood samples taken after 8 h and later showed maxima of (CH 3 ) 3 Bi concentrations for most participants; during the first 2 h after ingestion, no maxima were observed.
Discussion
This work represents the first in vivo study on bismuth biodisposition in humans, which includes the analysis of a volatile bismuth species. In addition to data on total bismuth uptake and elimination, which basically confirmed the results of previous studies on bismuth biodisposition (Slikkerveer and de Wolff, 1989; Klotz, 2000; Sun et al., 2004) , data on the identification and quantification of (CH 3 ) 3 Bi in blood and exhaled air samples are given.
Biodisposition and Elimination of Total Bismuth. After ingestion of colloidal bismuth subcitrate-containing tablets, bismuth levels in blood increased rapidly to a maximum. This is in line with previous reports. The early maxima of bismuth levels in blood suggest that some bismuth absorption may occur in the stomach and the upper sections of the intestine. Nwokolo et al. (1992) observed the persorption (transmucosal penetration) of bismuth particles in the gastric antral mucosa, which would explain the minor but rapid absorption of the ingested bismuth. Although every effort was made to ensure the standardization of the sampling and analytical procedures, the maxima of total bismuth concentration in blood varied by more than 2 orders of magnitude. These differences in bismuth absorption are not well understood, but factors such as variations in eating patterns before the study and the pH of the stomach may be implicated (Sun et al., 2004) . Animal studies have shown that the simultaneous p.o. administration of bismuth salts and thiolates increases the bismuth level in blood plasma (Williams, 1977; Chaleil et al., 1981) . Increased bismuth levels in blood have also been reported after an increase of intragastric pH by the application of ranitidine or omeprazole (Nwokolo et al., 1991; Treiber et al., 1994) : the solubility of colloidal bismuth subcitrate ranges from less than 1 mg/ml at acidic pH to several hundred milligram per milliliter in pure water (Sun et al., 2004) .
The elimination routes of total bismuth were exhaled air [up to 0.03‰ as (CH 3 ) 3 Bi)], urine (0.03-1.2%), and feces. Most of the bismuth was excreted via the fecal route, exposing the metal to the microflora of the intestine. It is interesting to note that this is not the case for arsenic, which is also an element of group 15 of the periodic system. Apart from the higher toxic potential of its inorganic forms, arsenic is predominantly eliminated via urine (Craig, 2003) . As a consequence of the predominant elimination of bismuth via feces, this metal is an ideal element to investigate intestinal biomethylation.
Identification and Quantification of (CH 3 ) 3 Bi. (CH 3 ) 3 Bi in exhaled air and blood was identified unambiguously in samples of all the study participants via GC/ICP-MS using a commercially available compound as a reference. This analytical approach was completed by the characterization of the reference compound by GC/EI-MS/ ICP-MS (Koesters et al., 2005) . The use of this novel but robust technique allowed the reliable monitoring of (CH 3 ) 3 Bi concentrations in exhaled air and blood samples, which provided strong evidence for the occurrence of (CH 3 ) 3 Bi in human matrices after bismuth ingestion. Quantification of (CH 3 ) 3 Bi was performed using an IAC method as described by Feldmann (1997) and as further validated by DiazBone and Hitzke (2008) .
Kinetics of (CH 3 ) 3 Bi. In comparison to the amount of bismuth ingested, only low concentrations of (CH 3 ) 3 Bi were measured in breath and blood. The courses of (CH 3 ) 3 Bi concentrations in both matrices were similar (Fig. 3) , which indicates a close relationship between the two compartments with respect to this volatile bismuth species. The occurrence of (CH 3 ) 3 Bi in exhaled air 2 h after bismuth ingestion points to a relatively rapid methylation process.
The big differences in AUCs observed in the individuals are a reflection of their different potential to methylate bismuth. The amount of exhaled bismuth was calculated from an average respiratory volume of 0.5 m 3 /h and the AUC. This value was used to obtain an estimate of eliminated bismuth via exhaled air.
In a few study participants, all the (CH 3 ) 3 Bi blood levels were below the limit of detection, whereas the accompanying (CH 3 ) 3 Bi concentrations in exhaled air were measurable. The variation coefficients of the measurements were generally in the range from 3 to 10%; the larger variations may be partly because of (CH 3 ) 3 Bi decomposition during sample preparation. Most maxima of (CH 3 ) 3 Bi concentrations were reached in the interval from 8 to 24 h after bismuth ingestion. Here, a differentiation between slower and faster methylation was observed (Fig. 4) . Because the number of sampling intervals was limited, precise concentration maxima, elimination patterns, and half-lives of (CH 3 ) 3 Bi could not be determined. The high variability observed in bismuth methylation may be either because of a gene polymorphism similar to that found for arsenic methylation in humans (Marnell et al., 2003; Drobná et al., 2004; Aposhian and Aposhian, 2006) or to a varying composition of the intestinal microflora, which has been shown to methylate bismuth ex situ (Michalke et al., 2007 (Michalke et al., , 2008 .
Origin of (CH 3 ) 3 Bi. Two scenarios are plausible for bismuth methylation in the human body: a microbial pathway with participation of microorganisms present in the intestine and an endogenous pathway as described for arsenic and other elements (Thayer, 2002; Aposhian and Aposhian, 2006) . Anaerobic incubation of feces samples obtained from volunteers after ingestion of bismuth showed that intestinal microorganisms are able to methylate bismuth ex vivo Michalke et al., 2007 Michalke et al., , 2008 . Finally, a strong indication that microbial methylation takes place in vivo was the detection of significant amounts of trimethylbismuth in freshly collected feces (Boertz, 2008) .
These observations in combination with the fact that bismuth is mainly excreted via feces are strong indications that methylation of bismuth takes place in the human intestine. After microbial volatilization of (CH 3 ) 3 Bi in the colon, this species diffuses into the blood and is then transferred to the lungs, from where it is exhaled.
Nevertheless, by the current data the participation of an abiotic or endogenous enzymatic pathway, in particular in the human liver, cannot be ruled out. Abiotic methylation of bismuth by methylcobalamine has been shown by Michalke et al. (2002) .
A possible indication of the endogenous contribution to the methylation of bismuth is the detection of small amounts of trimethylbismuth as early as 2 h after ingestion. Because the transport into the intestine normally requires a longer time period, it is unlikely that intestinal microorganisms account for (CH 3 ) 3 Bi production during this early period. Moreover, similar time profiles as observed in the present study for trimethylbismuth has been found for the methylated FIG. 3. (CH 3 ) 3 Bi concentrations in exhaled air and blood of two male volunteers. A rapid production of (CH 3 ) 3 Bi (a) and a slower production of (CH 3 ) 3 Bi (b). arsenic derivatives that are formed in the liver (Styblo et al., 1999; Yu, 1999) . Further studies will be necessary to differentiate the relative contribution of endogenous and microbial methylation of bismuth.
Toxicological Implication of Bismuth Volatilization. Only low concentrations of the volatile (CH 3 ) 3 Bi were detected in blood and exhaled air after ingestion of the bismuth-containing pharmaceutical. It has to be emphasized that a bismuth-containing species with increased toxicity was formed from a bismuth-containing drug by this metabolic step. Based on LD 50 values available for colloidal bismuth subcitrate (7047 mg/kg, mice, p.o.; Zhang et al., 2006) and for (CH 3 ) 3 Bi (484 mg/kg, rabbit, p.o.; Craig, 2003) , the acute toxicity increased by more than 1 order of magnitude. It should also be noted that the lipophilic potency of inorganic bismuth increases by methylation, which facilitates the crossing of membranes such as the bloodbrain barrier. It may be speculated that the encephalopathies diagnosed in the 1970s in French and Australian patients were associated with the formation of the volatile toxic (CH 3 ) 3 Bi species (Michalke et al., 2002) . These patients had taken bismuth salts for the treatment of duodenal ulcers for extended periods of time (Lowe, 1974; MartinBouyer, 1978) .
Outlook. In view of the continuing use of bismuth compounds as pharmaceuticals and the widespread exposure of people to bismuthcontaining cosmetics, there is a need for further studies on bismuth metabolism in the human body. In these studies, one should elucidate the influence of food on absorption and methylation of bismuth, the involvement of the intestinal microflora in the metabolic activity of a metal compound used as a drug, and the identification of the microorganisms that are responsible for bismuth methylation. Alternative bismuth-methylating pathways, if these are present, should also be investigated in detail, e.g., by characterizing the methylating enzyme systems in human liver cells after incubation with bismuth-containing compounds.
